There are 2934 resources available
1216 - The importance of primary surgery in patients with de novo stage IV BC survived at least 5- Year; Protocol MF07-01 Randomized Clinical Trial.
Presenter: Vahit Ozmen
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
2713 - Leuprorelin (LEUP) combined with Letrozole (LET) with/without Everolimus (EVE) in Ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550)
Presenter: Jaeho Jeong
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
Immunotherapy 101
Presenter: Christian Blank
Session: Immunotherapies: A revolution in cancer treatment, but are they accessible for all patients?
Resources:
Slides
Webcast
Case study: NSCLC
Presenter: Miklos Pless
Session: Immunotherapies: A revolution in cancer treatment, but are they accessible for all patients?
Resources:
Slides
Webcast
Innovative Medicines Initiative: Calling for research on immunotherapies?
Presenter: Kjetil Tasken
Session: Immunotherapies: A revolution in cancer treatment, but are they accessible for all patients?
Resources:
Slides
Webcast
Patient perspective
Presenter: Bettina Ryll
Session: Immunotherapies: A revolution in cancer treatment, but are they accessible for all patients?
Resources:
Slides
Webcast
EONS - Translating the YCN survey results into clinical practice: What is the way forward?
Presenter: Sara Parreira
Session: EONS 12: Collaborative session EONS YCN - ESMO YOC: Addressing the needs of young cancer professionals
Resources:
Slides
Webcast
Personalised oncogenomics: Is a precision approach necessary for every cancer or is there a therapy-driven bottleneck?
Presenter: David Huntsman
Session: Molecular tumour board: Where do we stand? What’s next?
Resources:
Slides
Webcast
Building of a comprehensive clinical and molecular genomics database for patients with treatment-refractory cancers enrolled in clinical trials
Presenter: Philippe Bedard
Session: Molecular tumour board: Where do we stand? What’s next?
Resources:
Slides
Webcast
Tissue and liquid biopsies with MTB for phase 1 trial selection: Experience in the TARGET trial
Presenter: Matthew Krebs
Session: Molecular tumour board: Where do we stand? What’s next?
Resources:
Slides
Webcast